ATE280783T1 - Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis - Google Patents

Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis

Info

Publication number
ATE280783T1
ATE280783T1 AT96939805T AT96939805T ATE280783T1 AT E280783 T1 ATE280783 T1 AT E280783T1 AT 96939805 T AT96939805 T AT 96939805T AT 96939805 T AT96939805 T AT 96939805T AT E280783 T1 ATE280783 T1 AT E280783T1
Authority
AT
Austria
Prior art keywords
psoriasis
antibodies
diagnosis
treatment
monoclonal anti
Prior art date
Application number
AT96939805T
Other languages
English (en)
Inventor
Casimiro Jose Enrique Montero
Dios Fraga Juan
Valladares Josefa Lombardero
La Vibora Langueruela
Rodriguez Rolando Perez
Blazquez Patricia Sierra
Bravo Blanca Rosa Tormo
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Application granted granted Critical
Publication of ATE280783T1 publication Critical patent/ATE280783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
AT96939805T 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis ATE280783T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
PCT/CU1996/000004 WO1997019111A2 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 y sus utilizaciones

Publications (1)

Publication Number Publication Date
ATE280783T1 true ATE280783T1 (de) 2004-11-15

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96939805T ATE280783T1 (de) 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis

Country Status (15)

Country Link
US (1) US6572857B1 (de)
EP (1) EP0807125B1 (de)
JP (1) JP4113929B2 (de)
KR (1) KR100533854B1 (de)
CN (1) CN1222540C (de)
AT (1) ATE280783T1 (de)
AU (1) AU722882B2 (de)
BR (1) BRPI9607171B1 (de)
CA (1) CA2210751C (de)
CU (1) CU22584A1 (de)
DE (1) DE69633717T2 (de)
DK (1) DK0807125T3 (de)
ES (1) ES2231826T3 (de)
PT (1) PT807125E (de)
WO (1) WO1997019111A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
EP1597275B1 (de) 2003-02-24 2010-08-18 Institut Pasteur ANWENDUNG DES CPn104 POLYPEPTIDS AUS CHLAMYDIA PNEUMONIAE ODER DESSEN ANTIKÖRPER ZUR DIAGNOSE EINER CHLAMYDIA INFEKTION
NZ578633A (en) * 2006-12-26 2012-03-30 Ct De Inmunolgia Molecular Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of b-chronic lymphocytic leukaemia
PL2119452T3 (pl) * 2006-12-26 2021-03-08 Centro De Inmunologia Molecular Kompozycja farmaceutyczna zawierająca przeciwciało monoklonalne anty-cd6 do zastosowania w diagnostyce i leczeniu reumatoidalnego zapalenia stawów
EP3181588A1 (de) 2008-01-11 2017-06-21 Adheron Therapeutics, Inc. Cadherin-11 antagonisten und verfahren zur behandlung entzündlichen gelenkerkrankungen
BRPI0822447A2 (pt) * 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo
NO2593128T3 (de) * 2010-07-15 2018-06-09
EP3578205A1 (de) 2010-08-06 2019-12-11 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
WO2013006474A2 (en) 2011-07-01 2013-01-10 Beckman Coulter, Inc. Regulatory t cells and methods of identifying, obtaining and using to treat immuno-based disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR102276745B1 (ko) 2013-07-23 2021-07-14 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
EP3052106A4 (de) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynukleotide zur codierung immunmodulierender polypeptide
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
EP3529274B1 (de) 2016-10-21 2024-04-17 Biocon Limited Monoklonaler antikörper und verfahren zur verwendung zur behandlung von lupus
JP2021515039A (ja) * 2018-02-27 2021-06-17 エクイリウム, インコーポレイテッドEquillium, Inc. 重症喘息を処置するための組成物および方法
EP3813951A1 (de) 2018-06-29 2021-05-05 City of Hope Gegen cd6 gerichtete chimäre antigenrezeptoren zur behandlung bestimmter autoimmunerkrankungen
CN113490511A (zh) 2019-02-26 2021-10-08 伊奎利厄姆股份有限公司 用于治疗狼疮的抗cd6抗体组合物和方法
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
AU2022344418A1 (en) 2021-09-08 2024-04-04 Centro De Inmunologia Molecular Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper- inflammatory response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723437A (en) * 1993-11-02 1998-03-03 Duke University CD6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Also Published As

Publication number Publication date
CN1222540C (zh) 2005-10-12
WO1997019111A2 (es) 1997-05-29
CU22584A1 (es) 1999-11-03
AU722882B2 (en) 2000-08-10
DK0807125T3 (da) 2005-03-14
BR9607171A (pt) 1997-11-11
US6572857B1 (en) 2003-06-03
JP4113929B2 (ja) 2008-07-09
EP0807125A2 (de) 1997-11-19
DE69633717T2 (de) 2006-02-02
DE69633717D1 (de) 2004-12-02
EP0807125B1 (de) 2004-10-27
KR100533854B1 (ko) 2006-09-20
CN1175957A (zh) 1998-03-11
BRPI9607171B1 (pt) 2016-07-19
AU7690596A (en) 1997-06-11
MX9705445A (es) 1998-06-30
CA2210751C (en) 2007-01-30
CA2210751A1 (en) 1997-05-29
KR19980701502A (ko) 1998-05-15
PT807125E (pt) 2005-03-31
ES2231826T3 (es) 2005-05-16
JPH11506017A (ja) 1999-06-02
WO1997019111A3 (es) 1998-02-12

Similar Documents

Publication Publication Date Title
ATE280783T1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DE69536017D1 (de) Methoden und zusammensetzungen für die behandlung von glomerulonephritis
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
DE69636760D1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
DE69637131D1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
ATE132197T1 (de) Monoklonale antikörper
DE820303T1 (de) p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES
HUP0103573A2 (hu) Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE407149T1 (de) Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente
DE3854267T2 (de) HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung.
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DE3786173T2 (de) Menschlicher monoklonaler antikörper und arzneimittel zur prophylaxe und behandlung von infektiösen krankheiten.
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE203680T1 (de) Konjugat zur behandlung von entzündungserkrankungen
DE69937057D1 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
DE60208040D1 (de) Anti-ssrp-1 monoklonale antikörper und hybridome zur deren herstellung
DE3779283D1 (de) Zwei-phasen-shampoo zur reinigung, pflege und medizinischen behandlung.
ATE76282T1 (de) Zwei-phasen-shampoo zur reinigung, pflege und medizinischen behandlung.
ATE94759T1 (de) Verwendung von dextransulfat, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen protatakarzinoms.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0807125

Country of ref document: EP